Agreement between Rectosigmoidoscopy and Colonoscopy Analyses of Disease Activity and Healing in Patients with Ulcerative Colitis

Jean Frédéric Colombel, Ingrid Ordás, Thomas A. Ullman, Paul Rutgeerts, Akiko Chai, Sharon O'Byrne, Timothy T. Lu, Julián Panés

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Background & Aims Endoscopy limited to the rectosigmoid colon is the standard technique used to measure endoscopic healing in ulcerative colitis (UC) clinical trials. We evaluated whether rectosigmoidoscopy adequately measures UC activity in the more proximal colon. Methods We analyzed data from a phase 2, placebo-controlled study that evaluated the efficacy and safety of etrolizumab in patients with moderate to severely active UC who had not responded to standard therapy. Central readers determined Mayo Clinic endoscopic subscores (MCSe) and ulcerative colitis endoscopic index of severity (UCEIS) scores from the rectosigmoid and proximal colon in videos of 331 examinations performed at baseline, week 6, and week 10. Rates of endoscopic healing (MCSe ≤ 1, MCSe = 0) and scores from rectosigmoidoscopy and colonoscopy analyses were compared among 239 examinations with endoscopic assessment proximal to the rectosigmoid colon. Results There was a high degree of correlation between findings from rectosigmoidoscopy vs colonoscopy in assessment of disease activity based on MCSe of 2 or higher (r = 0.84) or MCSe of 1 or higher (r = 0.96), or the UCEIS score (r = 0.92). In 230 of 239 videos, findings from rectosigmoidoscopy agreed with those from colonoscopy in the detection of active disease (MCSe ≥ 2; n = 205) or healing (MCSe ≤ 1; n = 25). In 9 videos (2 taken at baseline, 7 taken after treatment), colonoscopy found proximal disease activity not detected by rectosigmoidoscopy. Post-treatment discordance was more frequent in the placebo group, affecting assessment of efficacy at week 10. When endoscopic healing was defined as MCSe of 0, there were discordant findings from only 1 video. Conclusions There is a high degree of correlation in assessments of UC activity made by rectosigmoidoscopy vs colonoscopy. For detection of endoscopic healing (MCSe ≤ 1), colonoscopy found persistent proximal lesions in the placebo group, which affected efficacy analyses. When endoscopic healing was defined as MCSe of 0, the concordance between rectosigmoidoscopy and colonoscopy was nearly perfect.

Original languageEnglish (US)
Pages (from-to)389-395e3
JournalGastroenterology
Volume150
Issue number2
DOIs
StatePublished - Feb 1 2016
Externally publishedYes

Fingerprint

Colonoscopy
Ulcerative Colitis
Colon
Placebos
Endoscopy
Therapeutics
Clinical Trials
Safety

Keywords

  • Anti-Integrin
  • EUCALYPTUS
  • IBD
  • Inflammatory Bowel Disease

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Agreement between Rectosigmoidoscopy and Colonoscopy Analyses of Disease Activity and Healing in Patients with Ulcerative Colitis. / Colombel, Jean Frédéric; Ordás, Ingrid; Ullman, Thomas A.; Rutgeerts, Paul; Chai, Akiko; O'Byrne, Sharon; Lu, Timothy T.; Panés, Julián.

In: Gastroenterology, Vol. 150, No. 2, 01.02.2016, p. 389-395e3.

Research output: Contribution to journalArticle

Colombel, Jean Frédéric ; Ordás, Ingrid ; Ullman, Thomas A. ; Rutgeerts, Paul ; Chai, Akiko ; O'Byrne, Sharon ; Lu, Timothy T. ; Panés, Julián. / Agreement between Rectosigmoidoscopy and Colonoscopy Analyses of Disease Activity and Healing in Patients with Ulcerative Colitis. In: Gastroenterology. 2016 ; Vol. 150, No. 2. pp. 389-395e3.
@article{585a8f6edba948a49c7e0bfea3147eea,
title = "Agreement between Rectosigmoidoscopy and Colonoscopy Analyses of Disease Activity and Healing in Patients with Ulcerative Colitis",
abstract = "Background & Aims Endoscopy limited to the rectosigmoid colon is the standard technique used to measure endoscopic healing in ulcerative colitis (UC) clinical trials. We evaluated whether rectosigmoidoscopy adequately measures UC activity in the more proximal colon. Methods We analyzed data from a phase 2, placebo-controlled study that evaluated the efficacy and safety of etrolizumab in patients with moderate to severely active UC who had not responded to standard therapy. Central readers determined Mayo Clinic endoscopic subscores (MCSe) and ulcerative colitis endoscopic index of severity (UCEIS) scores from the rectosigmoid and proximal colon in videos of 331 examinations performed at baseline, week 6, and week 10. Rates of endoscopic healing (MCSe ≤ 1, MCSe = 0) and scores from rectosigmoidoscopy and colonoscopy analyses were compared among 239 examinations with endoscopic assessment proximal to the rectosigmoid colon. Results There was a high degree of correlation between findings from rectosigmoidoscopy vs colonoscopy in assessment of disease activity based on MCSe of 2 or higher (r = 0.84) or MCSe of 1 or higher (r = 0.96), or the UCEIS score (r = 0.92). In 230 of 239 videos, findings from rectosigmoidoscopy agreed with those from colonoscopy in the detection of active disease (MCSe ≥ 2; n = 205) or healing (MCSe ≤ 1; n = 25). In 9 videos (2 taken at baseline, 7 taken after treatment), colonoscopy found proximal disease activity not detected by rectosigmoidoscopy. Post-treatment discordance was more frequent in the placebo group, affecting assessment of efficacy at week 10. When endoscopic healing was defined as MCSe of 0, there were discordant findings from only 1 video. Conclusions There is a high degree of correlation in assessments of UC activity made by rectosigmoidoscopy vs colonoscopy. For detection of endoscopic healing (MCSe ≤ 1), colonoscopy found persistent proximal lesions in the placebo group, which affected efficacy analyses. When endoscopic healing was defined as MCSe of 0, the concordance between rectosigmoidoscopy and colonoscopy was nearly perfect.",
keywords = "Anti-Integrin, EUCALYPTUS, IBD, Inflammatory Bowel Disease",
author = "Colombel, {Jean Fr{\'e}d{\'e}ric} and Ingrid Ord{\'a}s and Ullman, {Thomas A.} and Paul Rutgeerts and Akiko Chai and Sharon O'Byrne and Lu, {Timothy T.} and Juli{\'a}n Pan{\'e}s",
year = "2016",
month = "2",
day = "1",
doi = "10.1053/j.gastro.2015.10.016",
language = "English (US)",
volume = "150",
pages = "389--395e3",
journal = "Gastroenterology",
issn = "0016-5085",
publisher = "W.B. Saunders Ltd",
number = "2",

}

TY - JOUR

T1 - Agreement between Rectosigmoidoscopy and Colonoscopy Analyses of Disease Activity and Healing in Patients with Ulcerative Colitis

AU - Colombel, Jean Frédéric

AU - Ordás, Ingrid

AU - Ullman, Thomas A.

AU - Rutgeerts, Paul

AU - Chai, Akiko

AU - O'Byrne, Sharon

AU - Lu, Timothy T.

AU - Panés, Julián

PY - 2016/2/1

Y1 - 2016/2/1

N2 - Background & Aims Endoscopy limited to the rectosigmoid colon is the standard technique used to measure endoscopic healing in ulcerative colitis (UC) clinical trials. We evaluated whether rectosigmoidoscopy adequately measures UC activity in the more proximal colon. Methods We analyzed data from a phase 2, placebo-controlled study that evaluated the efficacy and safety of etrolizumab in patients with moderate to severely active UC who had not responded to standard therapy. Central readers determined Mayo Clinic endoscopic subscores (MCSe) and ulcerative colitis endoscopic index of severity (UCEIS) scores from the rectosigmoid and proximal colon in videos of 331 examinations performed at baseline, week 6, and week 10. Rates of endoscopic healing (MCSe ≤ 1, MCSe = 0) and scores from rectosigmoidoscopy and colonoscopy analyses were compared among 239 examinations with endoscopic assessment proximal to the rectosigmoid colon. Results There was a high degree of correlation between findings from rectosigmoidoscopy vs colonoscopy in assessment of disease activity based on MCSe of 2 or higher (r = 0.84) or MCSe of 1 or higher (r = 0.96), or the UCEIS score (r = 0.92). In 230 of 239 videos, findings from rectosigmoidoscopy agreed with those from colonoscopy in the detection of active disease (MCSe ≥ 2; n = 205) or healing (MCSe ≤ 1; n = 25). In 9 videos (2 taken at baseline, 7 taken after treatment), colonoscopy found proximal disease activity not detected by rectosigmoidoscopy. Post-treatment discordance was more frequent in the placebo group, affecting assessment of efficacy at week 10. When endoscopic healing was defined as MCSe of 0, there were discordant findings from only 1 video. Conclusions There is a high degree of correlation in assessments of UC activity made by rectosigmoidoscopy vs colonoscopy. For detection of endoscopic healing (MCSe ≤ 1), colonoscopy found persistent proximal lesions in the placebo group, which affected efficacy analyses. When endoscopic healing was defined as MCSe of 0, the concordance between rectosigmoidoscopy and colonoscopy was nearly perfect.

AB - Background & Aims Endoscopy limited to the rectosigmoid colon is the standard technique used to measure endoscopic healing in ulcerative colitis (UC) clinical trials. We evaluated whether rectosigmoidoscopy adequately measures UC activity in the more proximal colon. Methods We analyzed data from a phase 2, placebo-controlled study that evaluated the efficacy and safety of etrolizumab in patients with moderate to severely active UC who had not responded to standard therapy. Central readers determined Mayo Clinic endoscopic subscores (MCSe) and ulcerative colitis endoscopic index of severity (UCEIS) scores from the rectosigmoid and proximal colon in videos of 331 examinations performed at baseline, week 6, and week 10. Rates of endoscopic healing (MCSe ≤ 1, MCSe = 0) and scores from rectosigmoidoscopy and colonoscopy analyses were compared among 239 examinations with endoscopic assessment proximal to the rectosigmoid colon. Results There was a high degree of correlation between findings from rectosigmoidoscopy vs colonoscopy in assessment of disease activity based on MCSe of 2 or higher (r = 0.84) or MCSe of 1 or higher (r = 0.96), or the UCEIS score (r = 0.92). In 230 of 239 videos, findings from rectosigmoidoscopy agreed with those from colonoscopy in the detection of active disease (MCSe ≥ 2; n = 205) or healing (MCSe ≤ 1; n = 25). In 9 videos (2 taken at baseline, 7 taken after treatment), colonoscopy found proximal disease activity not detected by rectosigmoidoscopy. Post-treatment discordance was more frequent in the placebo group, affecting assessment of efficacy at week 10. When endoscopic healing was defined as MCSe of 0, there were discordant findings from only 1 video. Conclusions There is a high degree of correlation in assessments of UC activity made by rectosigmoidoscopy vs colonoscopy. For detection of endoscopic healing (MCSe ≤ 1), colonoscopy found persistent proximal lesions in the placebo group, which affected efficacy analyses. When endoscopic healing was defined as MCSe of 0, the concordance between rectosigmoidoscopy and colonoscopy was nearly perfect.

KW - Anti-Integrin

KW - EUCALYPTUS

KW - IBD

KW - Inflammatory Bowel Disease

UR - http://www.scopus.com/inward/record.url?scp=84959532442&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84959532442&partnerID=8YFLogxK

U2 - 10.1053/j.gastro.2015.10.016

DO - 10.1053/j.gastro.2015.10.016

M3 - Article

VL - 150

SP - 389-395e3

JO - Gastroenterology

JF - Gastroenterology

SN - 0016-5085

IS - 2

ER -